News & Events about Oncternal Therapeutics Inc.
Maxim Group downgraded shares of Oncternal Therapeutics (NASDAQ:ONCT Get Rating) from a buy rating to a hold rating in a research report released on Tuesday, The Fly reports. Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut shares of ...
Globe Newswire
2 months ago
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal ...
Oncternal Therapeutics (NASDAQ:ONCT Get Rating) had its price target reduced by equities researchers at Oppenheimer from $14.00 to $9.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an outperform rating on the stock. Several other research ...
Globe Newswire
6 months ago
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an ...